Stocklytics Platform
Asset logo for symbol MIRM
Mirum Pharmaceuticals
MIRM62
$41.51arrow_drop_up0.82%$0.33
High Growth
Asset logo for symbol MIRM
MIRM62

$41.51

arrow_drop_up0.82%

Income Statement (MIRM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
EBIT-$10.30M-$20.43M-$21.07M-$31.77M-$27.81M
EBITDA-$4.24M-$14.58M-$15.41M-$26.37M-$25.14M
gross Profit$69.57M$57.64M$51.39M$46.95M$37.49M
NET Income-$14.23M-$24.63M-$25.27M-$33.14M-$23.58M
total Revenue$90.37M$77.87M$69.22M$69.55M$47.72M

Balance Sheet (MIRM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
cash Equivalents-----
net Debt$94.68M$83.31M$4.67M$21.81M$2.96M
stockholders Equity$232.02M$228.98M$234.60M$248.67M$269.08M
total Assets$667.89M$660.75M$651.96M$646.62M$650.64M
total Debt$317.65M$316.55M$307.52M$308.14M$306.02M
total Liabilities$435.86M$431.76M$417.35M$397.95M$381.56M

Cash Flow (MIRM)

itemSep 2024Jun 2024Mar 2024Dec 2023Sep 2023
financing Cash Flow$3.86M$7.29M$1.20M$1.77M$207.12M
free Cash Flow$13.80M-$14.58M$15.19M-$21.61M-$18.22M
investing Cash Flow-----$182.76M
operating Cash Flow$3.98M-$3.80M$15.21M-$16.61M-$18.22M

Mirum Pharmaceuticals (MIRM) Financials

Mirum Pharmaceuticals Inc (MIRM) is a biopharmaceutical company that focuses on developing therapies for patients with rare liver diseases. The company's financial performance is reflected in its income statement, which provides a detailed breakdown of its revenues and expenses. The income statement shows the company's gross profit, which is the difference between its total revenue and the cost of goods sold. This measure provides insight into the company's ability to generate profit on its products. Mirum Pharmaceuticals Inc (MIRM) has also reported its net income from stockholders, which represents the profit that is available to its shareholders after deducting all expenses and taxes.
In addition to its income statement, Mirum Pharmaceuticals Inc (MIRM) also discloses its balance sheet, which provides information about its assets, liabilities, and stockholders' equity. The balance sheet shows the company's total assets, which include its cash equivalents, net debt, and stockholders' equity. Cash equivalents represent the company's liquid assets that can be readily converted into cash. Net debt is the difference between the company's total debt and its cash equivalents, providing insight into its financial leverage. Stockholders' equity represents the residual interest in the assets of the company after deducting its liabilities.
Mirum Pharmaceuticals Inc (MIRM) also provides information about its cash flow, which shows the movement of cash in and out of the company. The cash flow statement breaks down the company's cash flow into three categories: operating cash flow, investing cash flow, and financing cash flow. Operating cash flow represents the cash generated or used by the company's core operations. Investing cash flow represents the cash used for investments in long-term assets. Financing cash flow represents the cash generated or used from activities such as issuing or repurchasing stock and taking on or repaying debt. Mirum Pharmaceuticals Inc (MIRM) also reports its free cash flow, which is the cash that is available for the company to invest in growth opportunities or distribute to its shareholders.
add Mirum Pharmaceuticals  to watchlist

Keep an eye on Mirum Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Take Your Investments to a Whole New Level